US3035977A - Piperidine: psycho-chemotherapeutic - Google Patents
Piperidine: psycho-chemotherapeutic Download PDFInfo
- Publication number
- US3035977A US3035977A US856896A US85689659A US3035977A US 3035977 A US3035977 A US 3035977A US 856896 A US856896 A US 856896A US 85689659 A US85689659 A US 85689659A US 3035977 A US3035977 A US 3035977A
- Authority
- US
- United States
- Prior art keywords
- piperidine
- tablets
- salts
- patients
- mental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title claims description 53
- 150000003839 salts Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- 206010020400 Hostility Diseases 0.000 claims description 7
- 206010039897 Sedation Diseases 0.000 claims description 5
- 230000036280 sedation Effects 0.000 claims description 5
- 206010004224 Belligerence Diseases 0.000 claims description 3
- 206010029216 Nervousness Diseases 0.000 claims description 3
- 230000016571 aggressive behavior Effects 0.000 claims description 3
- VODLZKHEKKGCBG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(7-hydroxy-4-methyl-2-oxochromen-3-yl)acetate Chemical compound O=C1OC=2C=C(O)C=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O VODLZKHEKKGCBG-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 19
- 238000011282 treatment Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 13
- QBYCQKCWJLHOCV-UHFFFAOYSA-N hydron;piperidin-1-ium;phosphate Chemical compound OP(O)(O)=O.C1CCNCC1 QBYCQKCWJLHOCV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 10
- 230000036506 anxiety Effects 0.000 description 10
- 150000003053 piperidines Chemical class 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000003340 mental effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000004547 Hallucinations Diseases 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 206010043268 Tension Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000380 hallucinogen Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 238000009498 subcoating Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GMDSJKPBEOJYCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;piperidine Chemical compound C1CC[NH2+]CC1.OC(=O)C(O)C(O)C([O-])=O GMDSJKPBEOJYCH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 N-methyl-3-piperidyldiphenylglycolate Chemical compound 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002633 shock therapy Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- CCODOIDFURPJTR-BTJKTKAUSA-N (Z)-but-2-enedioic acid piperidine Chemical compound C1CCNCC1.OC(=O)\C=C/C(O)=O CCODOIDFURPJTR-BTJKTKAUSA-N 0.000 description 1
- XZKRFLLLRFDYQT-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperidine Chemical compound C1CCNCC1.OC(=O)CC(O)(C(O)=O)CC(O)=O XZKRFLLLRFDYQT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241001401345 Piperia Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NGZWOGMNVJINFP-UHFFFAOYSA-N butanedioic acid;piperidine Chemical compound C1CCNCC1.OC(=O)CCC(O)=O NGZWOGMNVJINFP-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- CDIDCIDDYQNFDJ-UHFFFAOYSA-N hydron;piperidin-1-ium;sulfate Chemical compound OS(O)(=O)=O.C1CCNCC1 CDIDCIDDYQNFDJ-UHFFFAOYSA-N 0.000 description 1
- VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical group [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- FSDDNHGQVBYPDW-UHFFFAOYSA-N phthalic acid;piperidine Chemical compound C1CCNCC1.OC(=O)C1=CC=CC=C1C(O)=O FSDDNHGQVBYPDW-UHFFFAOYSA-N 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US856896A US3035977A (en) | 1959-12-03 | 1959-12-03 | Piperidine: psycho-chemotherapeutic |
| FR844275A FR759M (en, 2012) | 1959-12-03 | 1960-11-18 | |
| BE597276A BE597276A (fr) | 1959-12-03 | 1960-11-21 | compositions pharmaceutiques tranquillisantes et procédé de préparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US856896A US3035977A (en) | 1959-12-03 | 1959-12-03 | Piperidine: psycho-chemotherapeutic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3035977A true US3035977A (en) | 1962-05-22 |
Family
ID=25324731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US856896A Expired - Lifetime US3035977A (en) | 1959-12-03 | 1959-12-03 | Piperidine: psycho-chemotherapeutic |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3035977A (en, 2012) |
| BE (1) | BE597276A (en, 2012) |
| FR (1) | FR759M (en, 2012) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3124508A (en) * | 1964-03-10 | N-methylaminoethyl | ||
| US3167476A (en) * | 1965-01-26 | preparations acting on the central nervous | ||
| US3177209A (en) * | 1960-09-16 | 1965-04-06 | Kefalas As | Dihydroanthracene compounds |
| US3178347A (en) * | 1960-06-03 | 1965-04-13 | Bocher Gustave Marie Joseph | Psycho-equilibrating pyrrolidone carboxylic acid |
| US3192200A (en) * | 1963-03-05 | 1965-06-29 | Heinz M Wuest | 1-cycloalkyl methyl derivatives of 1, 4-benzodiazepine |
| US3211738A (en) * | 1965-10-12 | Cghso cghso cghso | ||
| US4411882A (en) * | 1978-12-21 | 1983-10-25 | Sandoz Ltd. | Galenical compositions |
| US5272155A (en) * | 1991-12-05 | 1993-12-21 | Abbott Laboratories | (+)-2-methylpiperidine as modulator of cholinergic systems |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490098A (en) * | 1948-07-14 | 1949-12-06 | Minnesota Mining & Mfg | Fluoropiperidine compounds |
| US2590126A (en) * | 1948-03-10 | 1952-03-25 | Searle & Co | Quaternary ammonium salts of 2, 6-lupetidine |
| US2872374A (en) * | 1955-02-02 | 1959-02-03 | Nat Drug Co | Muscle-relaxing tranquilizer compositions |
-
1959
- 1959-12-03 US US856896A patent/US3035977A/en not_active Expired - Lifetime
-
1960
- 1960-11-18 FR FR844275A patent/FR759M/fr active Active
- 1960-11-21 BE BE597276A patent/BE597276A/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2590126A (en) * | 1948-03-10 | 1952-03-25 | Searle & Co | Quaternary ammonium salts of 2, 6-lupetidine |
| US2490098A (en) * | 1948-07-14 | 1949-12-06 | Minnesota Mining & Mfg | Fluoropiperidine compounds |
| US2872374A (en) * | 1955-02-02 | 1959-02-03 | Nat Drug Co | Muscle-relaxing tranquilizer compositions |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3124508A (en) * | 1964-03-10 | N-methylaminoethyl | ||
| US3167476A (en) * | 1965-01-26 | preparations acting on the central nervous | ||
| US3211738A (en) * | 1965-10-12 | Cghso cghso cghso | ||
| US3178347A (en) * | 1960-06-03 | 1965-04-13 | Bocher Gustave Marie Joseph | Psycho-equilibrating pyrrolidone carboxylic acid |
| US3177209A (en) * | 1960-09-16 | 1965-04-06 | Kefalas As | Dihydroanthracene compounds |
| US3192200A (en) * | 1963-03-05 | 1965-06-29 | Heinz M Wuest | 1-cycloalkyl methyl derivatives of 1, 4-benzodiazepine |
| US4411882A (en) * | 1978-12-21 | 1983-10-25 | Sandoz Ltd. | Galenical compositions |
| US5272155A (en) * | 1991-12-05 | 1993-12-21 | Abbott Laboratories | (+)-2-methylpiperidine as modulator of cholinergic systems |
| WO1994018974A1 (en) * | 1991-12-05 | 1994-09-01 | Abbott Laboratories | (+)- 2-methylpiperidine as modulator of cholinergic systems |
Also Published As
| Publication number | Publication date |
|---|---|
| FR759M (en, 2012) | 1961-08-21 |
| BE597276A (fr) | 1961-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2892753A (en) | Central nervous system stimulant | |
| US5916925A (en) | Pharmaceutical composition for treatment of dementia | |
| US2890984A (en) | Pharmaceutical composition containing 2-(1, 2, 3, 4-tetrahydro-1-naphthyl)imidazo-line | |
| US3035977A (en) | Piperidine: psycho-chemotherapeutic | |
| Berger et al. | Unusual muscle relaxant and analgesic properties of N-isopropyl-2-methyl-2-propyl-1, 3-propanediol dicarbamate (carisoprodol) | |
| DE2625222C3 (de) | 13-Dithiacyclopentan-2-ylidenmalonsäureester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| CN102432483A (zh) | 乙酰左卡尼汀盐酸盐的制备方法及其药物用途 | |
| US3051620A (en) | Treatment of mental disturbances by chemotherapeutic means | |
| HUBBARD | Chemotherapy in captive marine mammals | |
| DE60035162T2 (de) | Ein ZNS-penetrierender NK-1-Rezeptor-Antagonist in Kombination mit einem antidepressiven oder einem anxiolytischen Wirkstoff zur Behandlung von Depression und Angst | |
| DE2743704C2 (de) | L- oder DL-Phenylglycine enthaltende Arzneimittel | |
| US3053736A (en) | Treatment of mental disturbances by chemotherapeutic means | |
| DE69028603T2 (de) | Arzneimittel für bessere gehirnwirkung | |
| US2537988A (en) | Sympatholytic compositions | |
| US3218232A (en) | Method for relieving depression and composition therefor | |
| US3196073A (en) | Method of tranquilizing with 1, 2-dihydroxy propane | |
| US3053731A (en) | Therapeutic composition containing 4, 6-dimethyl-3-pyridazone and process of inducing hypnosis and tranquilization therewith | |
| EP0472304A2 (en) | Pharmaceutical compositions containing therapeutically active organosilane derivatives and process for preparing same | |
| JP3842815B2 (ja) | 血管拡張剤による肝臓病および同様の症状の治療方法 | |
| JPH05163144A (ja) | アルツハイマー型痴呆改善剤 | |
| DE3686538T2 (de) | Verwendung von dibenz(cd,f)indol-derivaten zur praevention vom alkoholmissbrauch. | |
| US3632775A (en) | Method for the treatment of gasterophilus intestinalis | |
| WO2025162430A1 (zh) | 一种药物联用及其在预防或治疗神经退行性疾病中的用途 | |
| Baker | A controlled trial of ethylcrotonylurea | |
| de Leeuw et al. | Severe extrapyramidal syndrome in a dog caused by a Haloperidol (Serenase®) intoxication |